Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Community-acquired Pneumonia Clear all
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia

NCT00640926
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Radezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
San Diego, California • Sylmar, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Not applicable Interventional

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

NCT05568654
View directory record Official record
Conditions
Community-Acquired Pneumonia, Antimicrobial Stewardship, Point-of-Care Testing
Interventions
Rapid Diagnostic Testing, Pharmacist-led de-escalation
Diagnostic Test · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
28,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Vero Beach, Florida • Weston, Florida • Akron, Ohio + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

NCT00643227
View directory record Official record
Conditions
Pneumonia
Interventions
clarithromycin extended release (ER), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Sep 9, 2026, 3:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01168713
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia
Interventions
Levofloxacin, CEM-101
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
45
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 9, 2026, 3:05 AM EDT
Completed No phase listed Observational

Etiology of Community Acquired Pneumonia

NCT00471757
View directory record Official record
Conditions
Streptococcus Pneumonia, Haemophilus Influencae, Mycoplasma Pneumonia, Chlamydia Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Not applicable Interventional

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT05976581
View directory record Official record
Conditions
Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
Interventions
Electronic alert, Structured communication of test results
Behavioral
Lead sponsor
Jonathan Baghdadi
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Completed No phase listed Observational

An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

NCT03908632
View directory record Official record
Conditions
Coccidioidomycosis, Pneumonia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 9, 2026, 3:05 AM EDT
Active, not recruiting Not applicable Interventional

Discharge Stewardship in Children's Hospitals

NCT05826873
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
Interventions
Discharge antibiotic stewardship intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days to 18 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

NCT01605864
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Efficacy of ceftaroline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 9, 2026, 3:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia

NCT00118651
View directory record Official record
Conditions
Pneumonia
Interventions
Not listed
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 9, 2026, 3:05 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 9, 2026, 3:05 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

NCT07251465
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Receipt of PCV20
Biological
Lead sponsor
Pfizer
Industry
Eligibility
19 Years and older
Enrollment
846,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 4 Interventional

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

NCT00035347
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
IV azithromycin, ceftriaxone, oral azithromycin, IV levofloxacin, oral levofloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
22
States / cities
Birmingham, Alabama • Long Beach, California • Sylmar, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 9, 2026, 3:05 AM EDT
Terminated Not applicable Interventional Results available

OPEP Devices in Acute Inpatient Treatment of Pneumonia

NCT04540510
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
OPEP therapy, Standard care
Device · Other
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 9, 2026, 3:05 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 9, 2026, 3:05 AM EDT
Terminated Phase 4 Interventional

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

NCT00237445
View directory record Official record
Conditions
Pneumonia
Interventions
telithromycin, azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 9, 2026, 3:05 AM EDT
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 9, 2026, 3:05 AM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 9, 2026, 3:05 AM EDT